

### ICMJE Form for Disclosure of Potential Conflicts of Interest

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## **Intellectual Property.**

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes **Pending:** The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed:
The patent has been licensed to an entity, whether earning

royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Section 1. Identifying Inform	nation	
1. Given Name (First Name) Jessica	2. Surname (Last Name) Hellings	<sup>3. Date</sup> 03/22/23
4. Are you the corresponding author?	XYes No	
5. Manuscript Title Pharmacotherapy In Autis	m Spectrum Disorders, Includinç	g Older Drugs Warranting Trials
6. Manuscript Identifying Number (if you king 82880	now it)	
Section 2. The Work Under C	onsideration for Publication	
	g but not limited to grants, data monitoring boa	ernment, commercial, private foundation, etc.) for ard, study design, manuscript preparation, statistical
If yes, please fill out the appropriate inf Excess rows can be removed by pressin		e entity press the "ADD" button to add a row.
Name of Institution/Company	? ? ?	Comments
National Institute of Child He	alth and Human Development□	Previous program proje <mark>ct<b>★</b>o</mark> study r
University of Missouri-Kansas	s City internal funding to study a	mitriptyline in ASD
Section 3. Relevant financial	activities outside the submitted wor	·k.
of compensation) with entities as descri	ibed in the instructions. Use one line for ea port relationships that were <b>present durin</b>	inancial relationships (regardless of amount ach entity; add as many lines as you need by ag the 36 months prior to publication.
If yes, please fill out the appropriate inf	ormation below.	
Name of Entity	? ? ?	Comments
University of Missouri-Kansas	City	×
Interna	al funding to study amitriptyline ir	n ASD ADD

Do you have an	y patents, whether	planned, pend	ing or issue	d, broadly releva	ant to the work?	OYes <b>⊗</b> No	
	out the appropriate be removed by pre			ı have more thar	n one entity press	the "ADD" button to	add a row.
	<b>?</b>	ending?	?	?	Licensee?	Comments	
							×
							ADD
Section 5.	Relationships	not covered	above				
	relationships or act iencing, what you w				influenced, or the	at give the appearanc	e of
Yes, the follo	owing relationships	/conditions/cire	cumstances	are present (exp	olain below):		
	owing relationships, ationships/conditio					t	
No other relations At the time of n	ationships/conditio	ns/circumstand	es that pres	sent a potential o	conflict of interes	date their disclosure	statements.
No other relations At the time of n	ationships/conditio	ns/circumstand nce, journals wi nors to disclose	es that pres	sent a potential o	conflict of interes	date their disclosure	statements.
No other relative of no occasion, jo	nationships/condition nanuscript acceptar urnals may ask auth Disclosure Sta	ns/circumstand nce, journals wi nors to disclose tement	es that pres	rs to confirm and	conflict of interes d, if necessary, up eported relations	date their disclosure hips.	
No other relative of no occasion, jo	nationships/condition nanuscript acceptar urnals may ask auth Disclosure Sta	ns/circumstand nce, journals wi nors to disclose tement	es that pres	rs to confirm and	conflict of interes d, if necessary, up eported relations	date their disclosure	

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Jessica Hellings